Navigation Links
Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
Date:11/27/2007

HAYWARD, Calif., Nov. 27 /PRNewswire/ -- Singulex Inc. today announced that it is collaborating with researchers at Wyeth Research to develop immunoassays on the company's Erenna(TM) system. Singulex has installed the Erenna system at Wyeth as part of its Erenna Technology Access Program (ETAP) and has begun optimizing assays that will allow Wyeth to accurately and precisely measure specific biomarkers in human blood.

"Biomarkers play an important role in the evaluation of compounds in both drug discovery and development, and we are keenly interested in applying new and improved technologies in the measurements of biomarkers," said Ole Vesterqvist, Ph.D., senior director of the Biomarker Laboratory in Clinical Translational Medicine at Wyeth. "For example, with the right biomarker and technology, one can study the effects of a therapeutic intervention in clinical studies. However, many biomarkers are present in human blood at extremely low concentrations, making it difficult to accurately and precisely measure. Singulex has provided us with a new technology for detection of biomarkers at very low concentrations and we are currently validating several assays in our laboratory that should help us guide our clinical programs."

Singulex's proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company's flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species. Singulex was the first to identify and quantify normal levels and small changes of cardiac troponin I, a protein biomarker used to detect cardiotoxicity and heart attacks, in human plasma.

"Singulex's technology extends the clinical utility of new and existing biomarkers by removing the limits of detection," said Philippe Goix, Ph.D., president and CEO of Singulex. "The ability to detect normal and deviations from normal levels of biomarkers will enable better determination of therapeutic index for drug developers and researchers and help shorten the time to select and develop new therapies."

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Hayward, California. To learn more about Singulex, please visit us at http://www.singulex.com.

About ETAP

The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.


'/>"/>
SOURCE Singulex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Bacteria from sponges make new pharmaceuticals
2. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
3. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
4. A search for biomarkers for early detection of colorectal cancer
5. Research shows skeleton to be endocrine organ
6. Newly created cancer stem cells could aid breast cancer research
7. Dominant cholesterol-metabolism ideas challenged by new research
8. Researchers identify proteins involved in new neurodegenerative syndrome
9. Texas researchers and educators head for Antarctica
10. MGH researchers describe new way to identify, evolve novel enzymes
11. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology: